Revenue and Adjusted Profit Surpass Expectations, Leading to an Uptick in Assertio Holdings' Stock Price
Assertio Holdings, a pharmaceutical company, has announced its Q2 2025 financial results, with shares rising post market on Monday. The stock is up about 5% after the bell.
In Q2 2025, Assertio Holdings reported a revenue of approximately $29.2 million, marking a 6.1% decline year-over-year. This decrease was partly offset by stronger Rolvedon sales of about $16.1 million. Other revenue contributors included Sympazan ($3.2 million), INDOCIN products ($3.0 million), SPRIX ($2.0 million), and royalties ($0.4 million).
The company reported a widened net loss of about $16.4 million ($0.17 loss per share), significantly higher than the prior year's loss. This was partly affected by a $8.2 million loss on a divestiture and ongoing cost pressures including amortization of intangibles.
Despite the net losses, the company reported an adjusted EBITDA of $5.6 million, higher than the same period last year. Cash and investments increased to $98.2 million, aided by effective expense management including lower SG&A costs benefiting from tax credits.
Product highlights included Rolvedon sales growing to $16.1 million, confirming it as a key revenue driver in the portfolio despite the overall revenue decline. The company also announced that it has ceased commercialization of Otrexup.
CEO Brendan O'Grady stated that the company has narrowed its full year revenue guidance to a range between $108M to $118M, which compares to a consensus of $113.95M. The expected 2025 EBITDA for Assertio Holdings is between $11M and $19M.
Assertio's adjusted earnings were $0.02 per share, surpassing Street expectation by $0.03 per share. The revised guidance is lower than a previous range between $108M to $123M.
The Seeking Alpha's Quant Rating on Assertio Holdings is not provided in the given paragraph. For precise Q2 2022 figures for revenue, earnings, or Rolvedon sales, further targeted historical financial reports or SEC filings for that period would be required. If needed, I can help find Q2 2022-specific data or analyze Assertio’s longer-term trends including 2022.
In light of these financial results, investors may consider exploring potential investment opportunities in the pharmaceutical sector, given Assertio Holdings' growth in adjusted EBITDA and cash reserves. Despite the widened net loss, the company's focus on cost management and key revenue drivers like Rolvedon could attract business interest.
